Effect of Long-Term Tafamidis Treatment on Health-Related Quality of Life in Patients with Transthyretin Amyloid Cardiomyopathy
European Journal of Heart Failure · 2024
DOI: 10.1002/ejhf.3190 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Heart Failure, 2024. Verfasst von Martha Grogan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Quality of Life, Benzoxazoles, Amyloid Neuropathies, Familial, Cardiomyopathies. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Aims
To evaluate the effect of long-term tafamidis treatment on health-related quality of life (HRQoL) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) enrolled in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension (LTE) study. Methods and results We examined change from baseline in Kansas City Cardiomyopathy Questionnaire overall summary (KCCQ-OS) and clinical summary (KCCQ-CS) scores in patients who received tafamidis meglumine 80 mg for 30 months in ATTR-ACT and tafamidis (meglumine 80 mg or bioequivalent free acid 61 mg) for 30 months in the LTE study, and in patients who received placebo for 30 months in ATTR-ACT and tafamidis for 30 months in the LTE study. In ATTR-ACT, 176 and 177 patients were randomized to tafamidis 80 mg and placebo, respectively. Patients who continuously received tafamidis had a 6- to 7-point reduction in least squares (LS) mean (standard error) KCCQ-OS and KCCQ-CS scores at month 30 (−6.25 [1.53] and −7.48 [1.39]), with little or no further decline over the next 30 months (−5.92 [1.77] and −9.21 [1.88] at month 60). Patients who received placebo in ATTR-ACT had a 20-point reduction in LS mean KCCQ-OS and KCCQ-CS scores at month 30 (−19.60 [1.94] and −19.90 [2.01]), but the decline slowed after initiating tafamidis (−24.70 [3.04] and −25.30 [3.36] at month 60).
Conclusion
Tafamidis reduced HRQoL decline in patients with ATTR-CM. Patients continuously treated with tafamidis for 60 months demonstrated stabilized HRQoL. In patients who initially received placebo in ATTR-ACT, tafamidis reduced the decline in HRQoL during the LTE study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.
- University of British Columbia, Vancouver, BC, Canada.
- Cardiology, Complexo Hospitalario Universitario A Coruña (CHUAC): CIBERCV, Universidade da Coruña (UDC), Instituto de Investigacion Biomedicas A Coruña (INIBIC), A Coruña, Spain.
- Pfizer Inc, New York, NY, USA.
- Pfizer Inc, Groton, CT, USA.
- Pfizer Inc, Collegeville, PA, USA.
ORCID-Profile: Martha Grogan
Zitieren
APA
Grogan, M., Davis, M. K., Crespo-Leiro, M. G., Sultan, M. B., Gundapaneni, B., Stedile Angeli, F., & Hanna, M. (2024). Effect of Long-Term Tafamidis Treatment on Health-Related Quality of Life in Patients with Transthyretin Amyloid Cardiomyopathy. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3190
Vancouver
Grogan M, Davis MK, Crespo-Leiro MG, Sultan MB, Gundapaneni B, Stedile Angeli F, et al. Effect of Long-Term Tafamidis Treatment on Health-Related Quality of Life in Patients with Transthyretin Amyloid Cardiomyopathy. European Journal of Heart Failure. 2024. doi:10.1002/ejhf.3190
BibTeX
@article{Grogan2024,
author = {Grogan, Martha and Davis, Margot K and Crespo-Leiro, Maria G and Sultan, Marla B and Gundapaneni, Balarama and Stedile Angeli, Franca and Hanna, Mazen},
title = {Effect of Long-Term Tafamidis Treatment on Health-Related Quality of Life in Patients with Transthyretin Amyloid Cardiomyopathy},
journal = {European Journal of Heart Failure},
year = {2024},
doi = {10.1002/ejhf.3190}
}
EUVIMED